Seeking Alpha

Allergan (AGN) agrees to acquire MAP Pharmaceuticals (MAPP) for $958M ($25/share) in cash, a 60%...

Allergan (AGN) agrees to acquire MAP Pharmaceuticals (MAPP) for $958M ($25/share) in cash, a 60% premium over MAP's Tuesday close. MAP's experimental migraine drug Levadex is set to receive a regulatory decision by April 15; Botox maker Allergan (which already had rights to help market Levadex) is showing confidence in an OK by taking total control.
From other sites
Comments (1)
  • chanyerv@gmail.com
    , contributor
    Comments (2) | Send Message
     
    good stock I have made 36% in 2 years.
    23 Jan 2013, 07:09 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs